Asmin Tulpule
Overview
Explore the profile of Asmin Tulpule including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
471
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonzalez-Martinez D, Roth L, Mumford T, Guan J, Le A, Doebele R, et al.
Nat Commun
. 2024 Nov;
15(1):9473.
PMID: 39488530
Drug resistance remains a challenge for targeted therapy of cancers driven by EML4-ALK and related fusion oncogenes. EML4-ALK forms cytoplasmic protein condensates, which result from networks of interactions between oncogene...
2.
Reed D, Tulpule A, Metts J, Trucco M, Robertson-Tessi M, ODonohue T, et al.
J Clin Oncol
. 2024 Jun;
42(25):2955-2960.
PMID: 38843482
ALL cures require many MRD therapies. This strategy should drive experiments and trials in metastatic bone sarcomas.
3.
Menon S, Breese M, Lin Y, Allegakoen H, Perati S, Heslin A, et al.
Res Sq
. 2023 Jul;
PMID: 37398210
The genetic principle of synthetic lethality is clinically validated in cancers with loss of specific DNA damage response (DDR) pathway genes (i.e. BRCA1/2 tumor suppressor mutations). The broader question of...
4.
Menon S, Gracilla D, Breese M, Lin Y, Cruz F, Feinberg T, et al.
bioRxiv
. 2023 May;
PMID: 37205599
While oncogenes promote cancer cell growth, unrestrained proliferation represents a significant stressor to cellular homeostasis networks such as the DNA damage response (DDR). To enable oncogene tolerance, many cancers disable...
5.
Tulpule A, Guan J, Neel D, Allegakoen H, Lin Y, Brown D, et al.
Cell
. 2021 Apr;
184(10):2649-2664.e18.
PMID: 33848463
Receptor tyrosine kinase (RTK)-mediated activation of downstream effector pathways such as the RAS GTPase/MAP kinase (MAPK) signaling cascade is thought to occur exclusively from lipid membrane compartments in mammalian cells....
6.
Chatterjee N, Pazarentzos E, Mayekar M, Gui P, Allegakoen D, Hrustanovic G, et al.
Cell Rep
. 2019 Aug;
28(9):2317-2330.e8.
PMID: 31461649
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor and bi-functional lipid and protein phosphatase. We report that the metabolic regulator pyruvate dehydrogenase kinase1 (PDHK1) is...
7.
Kumar P, Gill R, Phelps A, Tulpule A, Matthay K, Nicolaides T
Cureus
. 2018 Jun;
10(4):e2527.
PMID: 29946497
Li-Fraumeni syndrome (LFS) is a rare cancer predisposition syndrome inherited in an autosomal dominant fashion that involves a germline mutation of tumor protein 53 (TP53). With the advent of more...
8.
Okimoto R, Breitenbuecher F, Olivas V, Wu W, Gini B, Hofree M, et al.
Nat Genet
. 2016 Nov;
49(1):87-96.
PMID: 27869830
Metastasis is the leading cause of death in people with lung cancer, yet the molecular effectors underlying tumor dissemination remain poorly defined. Through the development of an in vivo spontaneous...
9.
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely C, et al.
Nat Med
. 2015 Aug;
21(9):1038-47.
PMID: 26301689
One strategy for combating cancer-drug resistance is to deploy rational polytherapy up front that suppresses the survival and emergence of resistant tumor cells. Here we demonstrate in models of lung...
10.
Kelley J, Tulpule A, Daley G
Cell Cycle
. 2013 Oct;
12(22):3457-8.
PMID: 24107623
No abstract available.